Trinity Biotech plc completed its purchase of bioMérieux Inc.'s hemostasis, or coagulation, product line for up to $51.9 million, the company said Tuesday. As part of the deal, Trinity plans to move the line’s diagnostic tests and instruments production out of St. Louis.
